Benzinga's Microcap Movers for Friday July 13, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Opexa Therapeutics (NASDAQ: OPXA), the Woodlands, TX biopharmaceutical company, rose 85.98% Friday on 11 times average volume.
An Opexa spokesperson was not available for comment on the move. Shares have recently traded near the 52-week low.
Opexa Therapeutics closed at $0.69 on Friday.
Great Basin Gold
Great Basin Gold (NYSE: GBG), the South Africa-based mineral exploration company, rose 10.27% Friday on lower than average volume.
A research report Thursday mentioned Great Basin Gold as a possible takeover target.
Great Basin Gold closed at $0.56 on Friday.
Shares of Zogenix (NASDAQ: ZGNX), the San Diego, CA pharmaceutical company, rose 9.41% Friday on lower than average volume.
Zogenix announced Thursday that it has initiated its first IND clinical trial for Relday, a product candidate based on a combination of its DosePro needle-free, subcutaneous drug delivery system with a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia.
The Phase 1 clinical trial for Relday is a single-center, open-label, safety and pharmacokinetic trial that will enroll 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Zogenix expects that study results will be available by the end of 2012.
Zogenix closed at $2.21 on Friday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.